A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects
 on the body in healthy subjects and subjects with chronic heart failure with reduced ejection
 fraction
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
 visit www.BMSStudyConnect.com

 Inclusion Criteria:

 Healthy Subjects (Part A and B)

 -  Healthy subjects, as determined by no clinically significant deviations in medical
 history, physical examination, ECGs, vital signs, and clinical laboratory
 determinations

 -  Subjects must be willing and able to complete all study-specific procedures and visits

 -  Additional criterion for Japanese subjects in Groups BJ1 to BJ3: Subjects must be
 first generation Japanese (born in Japan and not living outside of Japan for > 10
 years, and both parents are ethnically Japanese)

 Heart Failure Patients (Part C)

 -  Left ventricular EF <45% and >25%, as assessed by cardiac MRI within 3 months of first
 dose of study drug; or left ventricular EF <40% and >25% as assessed by echocardiogram
 at Screening or within 3 months of first dose of study drug; left ventricular EF

 -  Heart failure is considered to be stable at the discretion of the Investigator (i.e.,
 no acute cardiovascular [CV] events or hospitalization (including emergency room
 visits) for CV causes within 3 months of first dose of study drug

 -  Regular sinus rhythm at Screening and no history of atrial fibrillation in the past 12
 months

 Exclusion Criteria:

 Healthy Subjects (Part A and B)

 -  Major surgery within 4 weeks of (first) study treatment administration

 -  Inability to be venipunctured and/or tolerate venous access

 -  Subjects who have smoked or used smoking cessation or nicotine containing products
 (including, but not limited, to e-cigarettes, pipes, cigars, chewing tobacco, nicotine
 patches, nicotine lozenges, or nicotine gum, varenicline, bupropion) within 6 months
 of the first dose of study drug

 Heart Failure Patients (Part C)

 -  Current or recent (within 3 months of study treatment administration) gastrointestinal
 disease that could affect absorption

 -  Major surgery within 4 weeks of (first) study treatment administration

 -  Inability to be venipunctured and/or tolerate venous access

 Other protocol defined inclusion/exclusion criteria could apply